MiMedx Launches AMNIOFIX Thyroid Shields After Study Shows 76% RLN Injury Reduction
MiMedx launched AMNIOFIX Thyroid Shields, dehydrated human amnion/chorion allografts for thyroidectomy, applied to RLN and parathyroid glands, shelf-stable five years. In a retrospective study of 670 treated versus 1,420 controls, RLN damage fell from 14.4% to 3.4% at 24-hour post-op (76% reduction).
1. Product Launch and Features
MiMedx introduced AMNIOFIX Thyroid Shields, a line extension of its dehydrated human amnion/chorion membrane allografts designed specifically for endocrine surgery. The preconfigured sheets attach directly to the exposed recurrent laryngeal nerve and parathyroid glands, require no intraoperative modification, and remain shelf-stable for up to five years thanks to the PURION® process.
2. Clinical Efficacy Demonstrated
A retrospective single-center study compared 670 thyroidectomy patients treated with AMNIOFIX Thyroid Shields against 1,420 matched controls and found a reduction in 24-hour postoperative RLN damage from 14.4% to 3.4%, representing a 76% decrease (p<0.01). All procedures were performed by the same surgeons using nerve monitoring endotracheal tubes.
3. Strategic Growth in Surgical Portfolio
The launch underlines MiMedx’s push into surgical applications beyond wound care and burns, leveraging proven placental allograft technology to address nerve injury concerns and potentially expand its market share in endocrine and other surgical specialties.